Blog

»  Posts By    

Frier Levitt Adds Daniel Giaquinto, Esq. and Guillermo Beades, Esq., Bolstering Their Liability and Regulatory Practice Group

As part of its continued expansion into the healthcare regulatory field, Frier Levitt announced today the hiring of two of the region's most reputable healthcare attorneys, Daniel G. Giaquinto, Esq., and Guillermo J. Beades, Esq. Already considered a national leader in healthcare regulatory as well as transactional matters, the new hires add even further depth to Frier Levitt. Mr. Giaquinto and Mr. Beades join the firm's Healthcare Regulatory Practice Group,...

Frier Levitt Attorneys Selected to the 2017 New Jersey Super Lawyers and 2017 Super Lawyers Rising Stars Lists

Frier Levitt is pleased to announce that four of the firm’s attorneys have been selected to the 2017 New Jersey Super Lawyers list and 2017 New Jersey Super Lawyers Rising Stars list. Co-Founding Partner Jonathan E. Levitt, Esq., was selected to his 12th straight overall New Jersey Super Lawyers list, having been selected to the New Jersey Super Lawyers since 2011 and previously to the New Jersey Super Lawyers Rising...

White Paper: “Performance” Based DIR Fees: A Rigged System with Disparate Effect on Specialty Pharmacies, Medicare Part D Beneficiaries and the U.S. Healthcare System

In this White Paper, the National Association of Specialty Pharmacy (NASP) and Frier Levitt explore the disparate impact that certain Pharmacy Benefit Managers (PBMs) "Direct and Indirect Remuneration" fees (commonly known as "DIR Fees") have on specialty pharmacies, Medicare beneficiaries and the healthcare system at large. It examines how some PBM-imposed DIR Fees, often calculated on a percentage of the total cost of the medication, have had a disparate impact...

DiGuglielmo Joins Frier Levitt as Counsel

Frier Levitt, LLC, a national boutique healthcare law firm, announced today that Theresa M. DiGuglielmo, Esq., has joined the firm as Counsel. Theresa rejoins the firm, having previously been an Associate in the firm’s Healthcare Department for ten years. Her Practice will focus primarily on regulatory and transactional matters. As a healthcare attorney, Theresa has enjoyed a varied practice and developed special areas of interest in medical supergroups, analyzing business...

White Paper: PBM DIR Fees Costing Medicare and Beneficiaries: Investigative White Paper on Background, Cost Impact, and Legal Issues

A White Paper by Frier Levitt examines the ongoing practice by Pharmacy Benefit Managers (PBMs) to increase corporate profits through murky "Direct and Indirect Remuneration" fees—commonly known as "DIR Fees"—charged to community oncology practices, as well as retail and specialty pharmacies (Pharmacy Providers). PBMs must report all discounts given after the drugs are sold to CMS. These are called "Direct and Indirect Remuneration" or "DIR." PBMs often receive additional discounts...